SuperworthRegeneron Pharmaceuticals REGN
- Market cap
- $82.9B
- PE
- 19.9×
- 10y median 19.7×
- Forward PE
- 12.6×
- 10y median 17.4×
- Price to sales
- 5.3×
- EV/EBIT
- 20.0×
- Revenue, 12 months
- $15.5B
- +9% on a year ago
- Net margin
- 27.9%
- Free cash flow yield
- 4.5%
Regeneron Pharmaceuticals trades at 19.9× trailing earnings, near its ten-year median. Revenue was $15.5B over the last twelve months, up 9% on a year earlier with a 28% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.4B+15% | $3.4B+1% | $3.1B−1% | $3.5B+12% | $3.7B+11% | $3.8B+10% | $3B−4% | $3.7B+4% | $3.8B+1% | $3.9B+3% | $3.6B+19% | $4.3B+17% | |
| Cost of revenue | $436.4M+37% | $517M−4% | $433.8M−5% | $480.2M+19% | $491.1M+13% | $565.4M+9% | $464.3M+7% | $530.2M+10% | $521.6M+6% | $584.6M+3% | $669.4M+44% | $576.5M+9% |
| Gross profit | $2.9B+12% | $2.9B+2% | $2.7B+0% | $3.1B+11% | $3.2B+10% | $3.2B+11% | $2.6B−5% | $3.1B+3% | $3.2B+0% | $3.3B+2% | $2.9B+15% | $3.7B+18% |
| R&D | $1.1B+18% | $1.2B+13% | $1.2B+13% | $1.2B+11% | $1.3B+18% | $1.4B+20% | $1.3B+6% | $1.4B+19% | $1.5B+16% | $1.6B+15% | $1.5B+16% | $1.6B+15% |
| SG&A | $640.5M+21% | $737.7M+12% | $689M+15% | $758.8M+16% | $714.4M+12% | $792.2M+7% | $633M−8% | $634.2M−16% | $657.8M−8% | $775M−2% | $647.7M+2% | $662.1M+4% |
| $1.1B−9% | $972.9M−15% | $751.4M−21% | $1.1B+5% | $1.2B+6% | $990.2M+2% | $591.7M−21% | $1.1B+1% | $1B−13% | $879.9M−11% | $642.9M+9% | $1.3B+20% | |
| Interest expense | $17.8M+16% | $18.3M+5% | $16.1M−11% | $14.8M−22% | $13.8M−23% | $10.5M−43% | $8.7M−46% | $3.6M−76% | $19.3M+40% | $12.2M+16% | $12.9M+48% | $11M+206% |
| Pre-tax income | $1.1B−26% | $1.1B−13% | $700.7M−18% | $1.6B+50% | $1.5B+34% | $958.1M−17% | $905M+29% | $1.5B−7% | $1.8B+18% | $1B+9% | $831.2M−8% | $1.5B+1% |
| $103M−47% | −$12M | −$21.3M | $195.8M+71% | $152.4M+48% | $40.4M | $96.3M | $127.1M−35% | $303.3M+99% | $199.1M+393% | $104M+8% | $230.9M+82% | |
| Net income | $1B−23% | $1.2B−3% | $722M−12% | $1.4B+48% | $1.3B+33% | $917.7M−21% | $808.7M+12% | $1.4B−3% | $1.5B+9% | $844.6M−8% | $727.2M−10% | $1.3B−7% |
| $8.89−24% | $10.20−3% | $6.27−13% | $12.41+46% | $11.54+30% | $8.08−21% | $7.27+16% | $12.81+3% | $13.62+18% | $7.84−3% | $6.75−7% | $12.23−5% | |
| 113.4M+1% | 113.7M−0% | 115.1M+1% | 115.4M+1% | 116.2M+3% | 113.6M−0% | 111.2M−3% | 108.6M−6% | 107.2M−8% | 107.7M−5% | 107.7M−3% | 106M−2% |
Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q2 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY09 to Q4 FY11: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 14 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $4.6B | $4.4B to $4.7B | $16.20 | $15.40 to $17.39 | 15 |
| Q4 FY26 | $5.3B | $4.6B to $5.9B | $20.33 | $15.63 to $26.71 | 13 |
| Q1 FY27 | $4.2B | $3.6B to $4.7B | $13.04 | $10.67 to $15.00 | 5 |
| Q2 FY27 | $4.8B | $4.1B to $5.3B | $15.97 | $13.07 to $18.37 | 5 |
| Q3 FY27 | $4.9B | $4.2B to $5.4B | $17.04 | $13.94 to $19.61 | 5 |
| Q4 FY27 | $5.2B | $4.5B to $5.8B | $18.84 | $15.41 to $21.67 | 5 |
Peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| VRTXVertex Pharmaceuticals | $132.8B | 30.5× | 28.6× | 27.0× | 10.6× | +10% | 35.0% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| Peer median | $19.7B | 34.0× | 39.9× | 27.0× | 7.5× | +22% | 22.9% |
More on Regeneron Pharmaceuticals
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 34Healthcare stocks with the lowest PEG ratio
- #5of 51Healthcare stocks with the lowest forward PE
- #6of 53Healthcare stocks with the fastest expected revenue growth
- #7of 29Biotech stocks with the highest profit margins
- #5of 16Biotech stocks with the lowest PE ratio
- #7of 18Biotech stocks with the highest free cash flow yield
- #10of 17Biotech stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .